Skip to main content
. 2017 Mar 31;6:e24051. doi: 10.7554/eLife.24051

Figure 1. Screen for modulators of ppGalNAc-T2/T3.

(A) Diagram showing sensor design and the linker sequences used. O-glycosylation of the linker masks the furin site but if an inhibitor blocks the ppGalNAc-transferase then furin cleaves the linker releasing the blocking domain (BD) allowing fluorescent activating protein (FAP) dimerization and dye activation. Linker furin sites are underlined and sites of glycosylation or mutation are in bold. (B) HEK cell lines with or without ppGalNAc-T2 or T3 stably expressing the WT or ∆glycan T2 or T3 sensor constructs (see linkers in A) were imaged in the presence of 110 nM of the dye MG11p (MG) to detect GFP or MG. Bar = 20 µm. (C) Schematic showing cell plating, drug treatment, cell release, fluorescence measurement and parallel analysis using both T2 and T3 sensors. Hits that activate both may be pan-specific or act on off-target pathways common to both sensors whereas sensor specific hits are likely acting directly on the corresponding ppGalNAc-transferase. (D) The plot shows Q values (Q=(R-RNeg)/SDNeg) for each compound (treatment at 10 µM for 6 hr) using the average of duplicate MG/GFP ratios for the compound (R), the vehicle-only control (RNeg), and the standard deviation of the vehicle-only controls (SDNeg). The cut-off values of +3 and −2.5 are indicated (*). Also indicated are the values for the positive controls (T2∆glycan and T3∆glycan) and the structure of the indicated T3-specific hit (inset). (E) Values (% enzyme activity relative to vehicle-only controls) in the in vitro assay using purified ppGalNAc-T2 or T3 as a secondary screen are shown for 20 hits from the primary screen. Compounds were present at 50 µM. Compound 1614 is T3Inh-1.

DOI: http://dx.doi.org/10.7554/eLife.24051.003

Figure 1—source data 1. Primary screen data for HEK cells expressing T2 or T3 sensors.
The accompanying spreadsheet shows calculated Q values (see Methods) for each compound tested. Note that autofluorescent compounds are left blank.
DOI: 10.7554/eLife.24051.004
Figure 1—source data 2. Secondary screen data (in vitro enzyme assays).
DOI: 10.7554/eLife.24051.005

Figure 1.

Figure 1—figure supplement 1. Cell growth at various T3Inh-1 exposures.

Figure 1—figure supplement 1.

Identical numbers of HEK cells were plated and grown in the continuous presence of the indicated concentrations of T3Inh-1 and then at 24, 48, or 72 hr they were released and counted. Averages are shown normalized using the untreated sample at 72 hr (n = 3 ± SEM).
Figure 1—figure supplement 1—source data 1. Cell counts at differing time points and T3Inh-1 concentrations.
DOI: 10.7554/eLife.24051.007

Figure 1—figure supplement 2. General N- and O-glycosylation are unaffected.

Figure 1—figure supplement 2.

(A, C, E, G) Representative fluorescent emission spectra from 510–550 nm of lysates obtained from HeLa cells treated with T3Inh-1 for 24 hr at 0, 10, or 20 µM. The cells were stained with the indicated lectin for 30 min just prior to analysis. (B, D, F, H) Quantified average staining values for the indicated lectins (at 520 nm emission) and T3Inh-1 treatments (n = 3 ± SEM).
Figure 1—figure supplement 2—source data 1. Fluorescent lectin staining of cells at differing T3Inh-1 concentrations.
DOI: 10.7554/eLife.24051.009

Figure 1—figure supplement 3. ppGalNAc-transferase levels are unaffected.

Figure 1—figure supplement 3.

(A) Representative images of untreated or T3Inh-1 treated (6 hr, 10 µM) HeLa cells after fixation and staining with antibodies against the indicated ppGalNAc-transferase and the Golgi marker GPP130. Bar = 10 µm.